INOVIO Reports 2025 Results as FDA Reviews Lead Drug Candidate
PLYMOUTH MEETING, PA — INOVIO (Nasdaq: INO) reported its 2025 financial results and said the U.S. Food and Drug Administration is reviewing its lead drug candidate, INO-3107, for a rare …
INOVIO Reports 2025 Results as FDA Reviews Lead Drug Candidate Read More